(Q39187613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Angelo Paci

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

C Jovelet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Deroussent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

R Farinotti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

J M Bidart

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S Gil

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

1 reference

28 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Drug Metabolism and Pharmacokinetics

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

149-157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23446814%20AND%20SRC:MED&resulttype=core&format=json

Role of tyrosine kinase inhibitors in cancer therapy

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Interaction of imatinib mesilate with human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Mechanism of multidrug recognition by MDR1/ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3

Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0123-3